Highlights
Profile claimed by owner
About
Psilocybin-based Treatments for Brain Pathologies
Ixtlan Bioscience is focused on developing a psilocybin-based treatment for Alzheimer's disease and other brain pathologies. The company is devoted to defining and utilizing psilocybin micro-dosing in order to find a new and better class of safe and accessible mental health therapies to slow down the progression of Alzheimer's and dementia diseases.
Identity
| Name | Ixtlan BioScience |
|---|---|
| Slug | ixtlan-bioscience |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4PmdwqkKDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Aug 2024 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Caesarea |
| HQ address | Caesarea, Israel |
Web & social
| https://www.linkedin.com/company/43364737 | |
| Twitter / X | https://twitter.com/IncIxtlan?t=702hIrcTIqQcZd9rI1xzOQ&s=08 |
| https://www.facebook.com/IxtlanBioscience |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentBiomaterials & Tissue Engineering
Technologies
BiologicalsHerbals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
patent-pendinghome-carebiopharmaceuticalalzheimers-diseasebiotechnologydata-analyticspharmaceuticalsnutraceuticalsbrain-disordermental-health
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}